次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

次世代がん診断の世界市場2015-2025年

NEXT-GENERATION CANCER DIAGNOSTICS MARKET FORECAST 2015-2025
Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年7月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文176ページになります。
商品コード:VGN433

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
次世代がん診断の世界市場規模は2015年段階で16億ドルに達すると推計され、2025年にかけて力強い成長が予測されます。当レポートで対象とする次世代癌診断は、NGS(次世代シーケンシング)、CTC検査(血中循環腫瘍細胞検査)、マイクロアレイ検査、先進PCR法、ISH(In Situ Hybridisation)などとなっています。NGSやCTCの市場参入、新興国市場の需要増大は市場の促進要因となるでしょう。
当レポートでは、2015年から2025年に至る次世代がん診断の世界市場予測、診断技術セグメント別市場予測、主要国別市場予測などの詳細予測データを掲載し、同技術のリーディング企業8社動向、市場トレンド、専門家オピニオン取材などの調査情報の詳説も盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】VGN433_Next-Generation Cancer Diagnostics Market Forecast 2015-2025 Cover.jpg
◆次世代がん診断の世界市場予測2015-2025年

◆診断技術セグメント別市場予測2015-25、および分析
・先進PCR法
・ISH (In-Situ Hybridisation)
・CTC検査:Circulating Tumour Cells (血中循環腫瘍細胞検査)
・マイクロアレイ検査
・NGS:Next Generation Sequencing(次世代シーケンシング技術)

◆主要国・地域別市場予測2015-25、および分析
・米国
・日本
・EU5国(英仏独伊西、合算値)
・中国
・インド
・ブラジル
・ロシア
・その他地域(Rest of the World)

◆リーディング企業8社動向
- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Thermo Fisher Scientific
- Agilent Technologies
- Hologic
- Illumina
- Myriad Genetics

◆市場動向分析
・早期診断スクリーニングによるコスト節約
・癌の有病率の増加傾向
・がん分子診断の認知度向上
・ゲノミクスおよびプロテオミクス情報量の飛躍的増大
・パーソナライズ医療の動向
・コンパニオン診断の採用拡大
・革新的な診断方法の出現

◆専門家オピニオンインタビュー:
- Keith Cannon, Executive Vice President, Aviva Biosciences
- Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma

◆調査結論
(全176ページ、87個のデータ表・グラフ類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

NEXT-GENERATION CANCER DIAGNOSTICS MARKET FORECAST 2015-2025
Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

Table of Contents

1. Executive Summary

1.1 Overview of Findings
1.2 Structure of the Report
1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics

2.1 What Is Cancer?
2.2 Cancer Diagnostics: An Overview
2.2.1 Screening
2.2.2 Diagnosis
2.2.3 Staging
2.3 Cancer Diagnosis Methods
2.3.1 Physical Examination
2.3.2 Imaging Techniques
2.3.2.1 Ultrasound
2.3.2.2 Computed Tomography (CT)
2.3.2.3 Magnetic Resonance Imaging (MRI)
2.3.2.4 Positron Emission Tomography (PET)
2.3.3 Histopathological and Cytological Techniques
2.3.4 Immunohistochemistry (IHC) Analysis
2.3.5 Circulating Tumour Cell (CTC) Analysis
2.3.6 Molecular Diagnostics and IVD
2.3.6.1 Polymerase Chain Reaction (PCR)
2.3.6.2 Multiplex PCR
2.3.6.3 Real-Time PCR (RT-PCR or qPCR)
2.3.6.4 Digital PCR (dPCR)
2.3.6.5 In Situ Hybridisation (ISH)
2.3.6.6 Microarray
2.3.6.7 Next-Generation Sequencing (NGS)
2.4 Tests for Inherited and Acquired Genetic Mutations
2.5 Companion Diagnostics (CDx)
2.6 Laboratory Developed Test (LDT)
2.7 Precision Medicine
2.8 Government Regulations
2.8.1 The US Approval and Regulation System
2.8.2 The EU Approval and Regulation System
2.9 Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2015-2025

3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 Biomarkers and Molecular Diagnostics
3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
3.5 Companion Diagnostics and Collaborations between Two Industries
3.6 LDTs to be Replaced by Approved Tests
3.7 Decentralisation of Diagnostic Tests
3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2015-2025

4. Next-Generation Cancer Diagnostics Submarkets 2015-2025

4.1 Advanced PCR Techniques
4.1.1 Advanced PCR Techniques Market Forecast 2015-2025
4.1.2 Leading Products in the Real-Time PCR Market
4.1.2.1 cobas 4800 System & Oncology Tests (Roche)
4.1.2.2 QuantStudio Dx & 7500 Fast Dx (Thermo Fisher)
4.1.2.3 Rotor-Gene Q & therascreen Tests (Qiagen)
4.1.2.4 Oncotype DX (Genomic Health)
4.1.3 Leading Products in the Digital PCR Market
4.1.4 Pap Tests Being Replaced by PCR Assays
4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
4.2 In Situ Hybridisation (ISH)
4.2.1 ISH Cancer Diagnostics Market Forecast 2015-2025
4.2.2 Leading Products in the ISH Cancer Diagnostics Market
4.2.3 HER2 Tests for Breast Cancer
4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
4.3 Circulating Tumour Cells (CTCs) Analysis
4.3.1 CTCs Analysis Market Forecast 2015-2025
4.3.2 Leading Product in the CTCs Analysis Market
4.3.2.1 CellSearch System (Janssen Diagnostics)
4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
4.3.4 CTCs Separation by Ultrasound
4.3.5 CTC Clusters More Likely to Cause Metastasis?
4.3.6 CTCs Analysis: Drivers and Restraints 2015-2025
4.4 Microarray
4.4.1 Microarray Cancer Diagnostics Market Forecast 2015-2025
4.4.2 Leading Products in the Microarray Market
4.4.2.1 OncoScan FFPE Assay Kit (Affymetrix)
4.4.2.2 MammaPrint (Agendia)
4.4.3 Microarray Cancer Diagnostics: Trends and Developments
4.4.3.1 Array Comparative Genomic Hybridisation (Array CGH)
4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
4.5 Next-Generation Sequencing (NGS)
4.5.1 NGS Cancer Diagnostics Market Forecast 2015-2025
4.5.2 Leading Products in the NGS Market
4.5.2.1 MiSeqDx (Illumina)
4.5.2.2 Ion PGM Dx System (Thermo Fisher)
4.5.2.3 GeneRead DNAseq Targeted Panels V2 (Qiagen)
4.5.3 NGS Cancer Diagnostics: Trends and Developments
4.5.3.1 Myriad Shifting from PCR to NGS Panel
4.5.3.2 Competition in the NGS Market
4.5.3.3 Bio-Rad to Commercialise NGS system for Clinical Use
4.5.3.4 Qiagen Launched NGS Bioinformatics Platform
4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025

5. Leading National Markets 2015-2025

5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2015-2025
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 US Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
5.2.2 Obama Launched 'Precision Medicine Initiative'
5.2.3 FDA and CMS to Regulate LDTs
5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.3.1 Germany: Leading Market in the EU
5.3.2 France: Reduction in Healthcare Spending
5.3.3 UK: 100,000 Genomes Project
5.3.4 Spain: Recovering from Financial Crisis
5.3.5 Italy: Decreasing Reimbursement
5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.5.1 Illumina Entering the Chinese Market
5.5.2 Epigenomics Colorectal Cancer Test Approved in China
5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.6.1 Lack of Genetic Testing Regulation
5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8.1 IBM’s Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2015

6.1 Roche Diagnostics
6.1.1 Roche Diagnostics: Product Portfolio, 2015
6.1.2 Roche Diagnostics: Diagnostics Outlook
6.1.3 Cobas HPV Test Approved in the US in 2014
6.1.4 Roche Diagnostics: Recent M&A Activity
6.1.5 Roche Coming Back to the NGS Business?
6.2 Abbott Laboratories
6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.2.2 Abbott: Diagnostics Outlook
6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
6.3 Qiagen
6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.3.1.1 Molecular Diagnostics Kits
6.3.1.2 Real-Time PCR: Rotor-Gene Q
6.3.1.3 Bioinformatics for NGS
6.3.2 Qiagen: Market Outlook
6.3.3 HalioDx Created from Qiagen Marseille
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific: Business Segments
6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.4.2.1 QuantStudio 3D (Digital PCR)
6.4.2.2 In Situ Hybridisation
6.4.2.3 Microarray Slides
6.4.2.4 Next-Generation Sequencing
6.4.2.5 Real-Time PCR for Oncology in Pipeline?
6.4.3 Thermo Fisher: Life Sciences Outlook
6.4.4 NGS Oncomine Focus Assay for Oncology Research
6.5 Agilent Technologies
6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.5.1.1 NGS Enrichment Platforms
6.5.1.2 Cytogenetic Research and Microarrays
6.5.1.3 Other Products
6.5.2 Agilent: Life Sciences and Diagnostics Outlook
6.5.3 Partnerships and Collaborations for Companion Diagnostics
6.6 Hologic
6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.6.1.1 Aptima HPV Assay and Cervista HPV Assay
6.6.1.2 Progensa PCA3 Assay
6.6.2 Hologic: Diagnostics Sales Outlook
6.7 Illumina
6.7.1 Illumina: Technology and Product Portfolio 2015
6.7.1.1 Sequencing Technology
6.7.1.2 BeadArray Microarray
6.7.1.3 Consumables
6.7.1.4 Services
6.7.2 Illumina: Sales Outlook
6.7.3 Illumina: Recent M&A Activity
6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
6.7.6 Investing on Synthetic DNA Manufacturing Technology
6.8 Myriad Genetics
6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.8.2 Myriad: Sales Outlook
6.8.3 New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2015-2025

7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
7.2 Strengths
7.2.1 Global Cancer Rates Set to Soar
7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
7.2.3 The Trend in Precision Medicine
7.3 Weaknesses
7.3.1 Industry Facing Increasing Reimbursement Pressure
7.3.2 Physicians’ Reliance on Traditional Methods
7.4 Opportunities
7.4.1 Expanding Biomarkers and Cancer Test Menus
7.4.2 Emerging Market to Provide Future Growth
7.4.3 Companion Diagnostics on the Rise
7.5 Threats
7.5.1 Decreasing Healthcare Spending
7.5.2 Gene Patenting Banned in the US?

8. Research Interviews

8.1 Keith Cannon, Executive Vice President, Aviva Biosciences
8.1.1 Aviva: From Research Laboratories to Clinical and Diagnostic Markets
8.1.2 Ability to Distinguish CTCs is the Key
8.1.3 RedSift(TM): Automated Enrichment of Nucleated Cells
8.1.4 On Drivers and Restraints in the CTC Technologies Market
8.1.5 On the Growth in Regional Markets
8.2 Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
8.2.1 On Future Growth of Oncolys BioPharma
8.2.2 CTCs is Changing the Market
8.2.3 On Current Restraints in the Market
8.2.4 ctDNA May Compete with Oncolys BioPharma’s TelomeScan

9. Conclusions

9.1 The World Next-Generation Cancer Diagnostics Market
9.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
9.1.2 Notable Next-Generation Cancer Diagnostics Companies
9.1.3 Leading Regional Markets
9.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2015-2025
9.2 The Future of the Next-Generation Cancer Diagnostics Market

10. Glossary

List of Tables

Table 1.1 Leading National Next-Generation Cancer Diagnostics Market Forecast 2015-2025 ($m, AGR%, CAGR%)
Table 3.1 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 3.2 Selected Biomarkers For Cancer Diagnostics
Table 3.3 FDA Approved Nucleic Acid Based Tests, 2015
Table 3.4 Selected Molecular Diagnostic Tests for Breast Cancer, 2015
Table 3.5 Selected Molecular Diagnostic Tests for Prostate Cancer, 2015
Table 3.6 Selected Molecular Diagnostics Test for Colorectal Cancer, 2015
Table 3.7 Companion Diagnostic Devices Approved by FDA, 2015
Table 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.2 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.3 CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.4 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.5 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 5.2 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.1 Roche: Overview, 2015
Table 6.2 Roche Diagnostics: Key Instrument/Device Launches Planned for 2015
Table 6.3 Roche Diagnostics: Key Test Launches Planned for 2015
Table 6.4 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.5 Abbott Laboratories: Overview, 2015
Table 6.6 Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.7 Qiagen: Overview, 2015
Table 6.8 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.9 Thermo Fisher: Overview, 2015
Table 6.10 Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2014
Table 6.11 Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
Table 6.12 Agilent: Overview, 2015
Table 6.13 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.14 Hologic: Overview, 2015
Table 6.15 Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.16 Illumina: Overview, 2015
Table 6.17 Illumina: Sequencing Product Portfolio 2015
Table 6.18 Illumina: Microarray Product Portfolio 2015
Table 6.19 Illumina: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.20 Myriad: Overview, 2015
Table 6.21 Myriad: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2015-2025

List of Figures

Figure 1.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 1.2 Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2015
Figure 3.1 Most Common Causes of Cancer Death, 2012
Figure 3.2 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 3.3 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2014
Figure 3.4 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2019
Figure 3.5 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2025
Figure 3.6 Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2015-2025
Figure 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.2 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
Figure 4.3 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.5 CTCs Analysis Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.6 CTCs Analysis: Drivers and Restraints 2015-2025
Figure 4.7 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.8 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.9 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.10 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 5.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 5.2 World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2014-2025
Figure 5.3 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2014
Figure 5.4 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2019
Figure 5.5 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2025
Figure 5.6 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.7 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.8 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.9 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.10 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.11 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.12 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.1 Roche Diagnostics: Revenue Share (%) by Segment, 2014
Figure 6.2 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.3 Roche Diagnostics: Growth Rate (%) by Region, 2014
Figure 6.4 Abbott: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.5 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.6 Life Technologies: Revenue ($m), AGR (%), 2008-2012
Figure 6.7 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.8 Hologic: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.9 Illumina: Revenue Share (%) by Business Segment, 2014
Figure 6.10 Illumina: Revenue Share (%) by Geographic Area, 2014
Figure 6.11 Illumina: Revenue ($m), AGR (%), 2010-2014
Figure 6.12 Myriad: Revenue ($m), AGR (%), 2010-2014
Figure 6.13 Myriad: Revenue Share by Product (%), 2013
Figure 6.14 Myriad: Revenue Share by Product (%), 2014

掲載企業リスト

Companies Listed

454 Life Sciences
Abbott Laboratories
AbbVie
AbVitro
Advanced Cell Diagnostics
Advanced Liquid Logic
Affymetrix
Agendia
Agilent Technologies
Ambry
Amgen
Annoroad
Applied Biosystems
ARCH Venture Partners
AstraZeneca
Atossa Genetics
AvanSci
Aviva Biosciences
BD
Berry Genomics
BGI
Bina Technologies
Biobase
Biochain
BioFluidica
BioMarin Pharmaceutical
bioMérieux
Bio-Rad
BioServe India
BlueGnome
Bristol-Myers Squibb
Bruker
Cancer Genetics
Cepheid
CLC bio
CompanionDx
Counsyl
Crescendo Bioscience
CytoTrack
Dako
DakoCytomation
Danaher
DiagnoCure
DxS
Eli Lilly
Enzymatics
Epic Sciences
Epicentre Technologies
Epigenomics
Exact Sciences
Fidelity Management
Fluidigm
Fluxion
GeneDx
Genentech
Genia Technologies
Genomic Health
Gen-Probe
GnuBio
HalioDX
Hitachi High-Technologies
Hologic
Idaho Technology
IGEN International
Illumina
Ingenuity Systems
Insilico Medicine
Invitae
Invitrogen
Ipsogen
Iquum
Iris Molecular Diagnostics
Janssen Biotech
Janssen Diagnostics
LabCorp
Life Technologies
Luminex Corporation
Manostring Technologies
Merck
Miltenyi Biotec
Mylan
Myraqa
Myriad Genetics
NextBio
Oncolys BioPharma
Ono Pharmaceutical
Oxford Nanopore
Pacific Biosciences
Pathway Genomics
Pathway Pharmaceuticals
Pensabio
PerkinElmer
Pfizer
Prosigna
Qiagen
Qiagen Marseille
Quest Diagnostics
Quidel
RainDance Technologies
Rarecells
Roche Diagnostics
Sakura
Sanofi
ScreenCell
Siemens
Signature Diagnostics
Silicon Biosystems
SRI Biosciences
Stratos Genomics
Sysmex
Takeda
Thermo Fisher Scientific
Twist Bioscience
Ventana Medical Systems
Verinata Health
Vysis

Other Organisations Mentioned in This Report

Actionable Genome Consortium
Arizona State University
Carnegie Mellon University
First Oncology Research and Advisory Center
Genomics England
Institut Curie
MGH Cancer Center
Massachusetts Institute of Technology
National Cancer Center
Paris-Descartes University
Pennsylvania State University

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。